Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | ALPG | P10696 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 14/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | PLEC | Q15149 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 12/20 | 0.50 |
| ▸ | CA2 | P00918 | 12/20 | 0.50 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30179280 | 1.00 | USP2 (0.62) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL29399313 | 0.97 | USP2 (0.58) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL29415506 | 0.94 | USP2 (0.56) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL2054802 | 0.94 | USP2 (0.56) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL3728723 | 0.93 | USP2 (0.57) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL12238065 | 0.89 | USP2 (0.47) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL31327372 | 0.88 | USP2 (0.50) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL20912026 | 0.86 | USP2 (0.57) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL29352834 | 0.86 | USP2 (0.56) | USP2L3MBTL1MEN1POLBKMT2A | |
| SCHEMBL6693395 | 0.86 | USP2 (0.56) | USP2L3MBTL1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220082501-A1 | FLUORESCENCE QUENCHING IMMUNOASSAY | IDEXX LABORATORIES, INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2021211969-A2 | FLUORESCENCE QUENCHING IMMUNOSSAY | IDEXX LABORATORIES, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| EP-3116525-B1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | UNIV CALIFORNIA (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210060188-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-03-04 | — | — | US | disclosed |
| WO-2020225077-A1 | PYRIMIDO[4,5-B]INDOL DERIVATIVES AS PDHK1 INHIBITORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-11-12 | — | — | WO | disclosed |
| US-10806807-B2 | TCO conjugates and methods for delivery of therapeutic agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-20 | — | — | US | disclosed |
| US-10408843-B2 | Compositions and methods for detecting S-nitrosylation and S-sulfinylation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-09-10 | — | — | US | disclosed |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-08-27 | — | — | US | disclosed |
| US-10342882-B2 | TCO conjugates and methods for delivery of therapeutic agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-09 | — | — | US | disclosed |
| US-10337317-B2 | Wax tracers | INSTITUTT FOR ENERGITEKNIKK (NO) | 2019-07-02 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-7247734-B2 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-07-24 | — | — | US | disclosed |
| WO-2007053358-A2 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2006095234-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2006-09-14 | — | — | WO | disclosed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| EP-1456180-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | Vernalis (Oxford) Ltd (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003055860-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342882-B2 | TCO conjugates and methods for delivery of therapeutic agents | FCGR2A, PAICS, CD47 | USP2 2957/4885L3MBTL1 796/4885MEN1 1382/4885 |
| US-20210060188-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | FCGR2A, PAICS, CD47 | USP2 2957/4885L3MBTL1 796/4885MEN1 1382/4885 |
| US-20220082501-A1 | FLUORESCENCE QUENCHING IMMUNOASSAY | NQO2, FCGRT, MPO | USP2 1703/4885L3MBTL1 2835/4885MEN1 3279/4885 |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | BRD4, BRDT, BRD3 | USP2 1670/4885L3MBTL1 1160/4885MEN1 3205/4885 |
| US-10806807-B2 | TCO conjugates and methods for delivery of therapeutic agents | FCGR2A, PAICS, CD47 | USP2 2957/4885L3MBTL1 796/4885MEN1 1382/4885 |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | USP2 2347/4885L3MBTL1 1731/4885MEN1 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.